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Eﬀ ectiveness of oral cholera vaccine in Haiti
Although killed, whole-cell oral cholera vaccines (OCVs) 
have been known to be eﬃ  cacious since 1986,1 and 
the bivalent whole-cell vaccine Shanchol has been 
licensed in India since 2009,2 OCV was not regarded as 
useful for controlling cholera outbreaks until recently.2 
Many public health oﬃ  cials questioned the use of OCV,3 
including concerns about its cost, the feasibility of 
undertaking large campaigns, the acceptability of OCV 
among vaccinated communities, and the possibility 
of diverting resources from other interventions. 
There was also uncertainty as to whether the vaccine, 
although known to be eﬀ ective in endemic countries 
(eg, India or Bangladesh), would be eﬀ ective in areas 
without a history of cholera, such as Haiti. When the 
cholera epidemic started in Haiti, Shanchol was not 
yet prequaliﬁ ed by WHO, and only a limited supply was 
available, so vaccination of large numbers of people was 
not realistic. Assuming eﬀ ectiveness in Haiti, and if the 
vaccine had been available and had been used earlier, 
computer models suggest it could have averted many 
cases and deaths.4–6
Although cholera vaccine was not used in the ﬁ rst two 
main waves of the epidemic, pilot projects were done 
in 2012 to deliver Shanchol to about 100 000 people in 
urban and rural Haiti.7,8 Subsequently, the Ministry of 
Health undertook larger campaigns in 2013, and plan 
to implement additional OCV campaigns in the coming 
years. Furthermore, the Ministry of Health has included 
the use of OCV in its national strategy for elimination of 
cholera, along with a continuing eﬀ ort to improve water 
and sanitation. The earlier reports7,8 showed that OCV 
was acceptable and that OCV campaigns were feasible 
in Haiti, but a new report by Louise Ivers and colleagues9 
in The Lancet Global Health provides important new 
information, showing that the vaccine’s eﬀ ectiveness in 
Haiti is comparable to that found in endemic countries of 
Asia and Africa.10 Of 47 people with cholera, 33 (70%) self-
reported vaccination versus 167 (89%) of 188 controls 
(vaccine eﬀ ectiveness 63%, 95% CI 8–85). Conversely, 
there was no association between self-reported or 
veriﬁ ed vaccination and non-cholera diarrhoea (vaccine 
eﬀ ectiveness 18%, 95% CI –208 to 78 by self-report and 
–21%, –238 to 57 by veriﬁ ed vaccination).
Similar eﬃ  cacy and eﬀ ectiveness of the two killed 
OCVs—Dukoral and Shanchol—has been documented. 
The two vaccines diﬀ er in that Dukoral is more expensive 
and is administered in a glass of buﬀ er solution to 
preserve the B subunit component of the vaccine, 
which increases the logistic requirements for its use. By 
contrast, Shanchol, which has no B subunit, needs no 
buﬀ er, is less costly, and consists of only 1·5 mL liquid, 
which can be consumed directly from a vial. Shanchol 
is now available through the OCV stockpile, which is 
supported partly by the Global Alliance for Vaccines and 
Immunization. It is being used primarily as a response to 
an outbreak, but it will probably also be used for groups 
at risk in endemic areas. Clearly, much work is needed 
to identify how best to use the vaccine in a manner that 
maximises its cost-eﬀ ectiveness.11
Some of the limitations of this study are related to 
the small sample size, which is a common problem 
in cholera eﬀ ectiveness studies and which limits 
the ability to discern diﬀ erences among subgroups. 
In this study, the point estimates diﬀ ered in some 
subgroup comparisons (eg, age group and time since 
vaccine administration), but the sample was not 
powered to identify whether these diﬀ erences were 
real. Ivers and colleagues9 were also not able to assess 
the potential for herd protection, which was found in 
other studies.12,13 Although OCV protects vaccinated 
individuals, it also lowers the risk for unvaccinated 
neighbours if vaccine coverage is suﬃ  ciently high. 
Modelling work predicted that 50% coverage could 
avoid transmission in endemic areas.14 Thus, further 
studies are needed to better understand how to 
maximise the eﬀ ect of herd protection.
Because the vaccine is in short supply and because 
providing two doses is logistically more complex and 
costly than providing only one dose, there is interest in 
the use of a single dose, which allows vaccination for 
twice as many people with the same amount of vaccine. 
Studies are underway to assess the eﬃ  cacy of a single 
dose and to compare the cost-eﬀ ectiveness of a single-
dose versus a two-dose regimen. Even if a single dose 
yields a lower level of eﬀ ectiveness, it may still prevent 
more cases in a population than a two-dose strategy 
because the target population can be expanded, 
especially in outbreak settings. The ﬁ eld eﬀ ectiveness 
of and the situations in which a single-dose strategy is 
appropriate still need to be identiﬁ ed.
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Some additional constraints of the vaccine should be 
mentioned. The vaccine is registered to be kept cold, 
but the cold chain requirement adds to the logistics and 
cost of the campaign. The main antigen of Shanchol 
is a lipopolysaccharide, which is thermostable; hence, 
Shanchol has a vaccine vial monitor (VVM) category 14 
(ie, if the vaccine is kept at 37°C, the colour endpoint at 
which discarding the vaccine is advised will be reached 
after 14 days). Extension to VVM category 30 would 
improve ﬂ exibility and reduce costs for campaigns.
Following previous practice, Ivers and colleagues9 
excluded pregnant women. Unfortunately, there is 
no coherence between the position of WHO, which 
recommends OCV for pregnant women because of their 
increased risk of complications and death when infected 
by cholera, and the package inserts, which stress the 
scarcity of safety data during pregnancy. Shanchol is a 
killed oral vaccine and is therefore expected to be safe, 
but additional data are needed to reassure regulators 
with regard to use during pregnancy. 
Finally, will OCV eliminate cholera from Haiti? By itself, 
this seems unlikely, but when combined with improved 
water and sanitation, health education, and high-
quality treatment, OCV can play a major part in reducing 
this infection to low levels and quicker than if OCV is not 
included in the plan. 
The ﬁ ndings in this Article conﬁ rm that Shanchol 
is eﬀ ective to protect individuals against cholera in 
endemic, epidemic, and intermediate contexts, and it 
complements previous work done by this group, which 
proved that OCV campaigns are feasible, well accepted, 
and can help to improve hygiene, water, and sanitation 
practices in vaccinated communities if they are well 
organised.15 These research studies should serve to 
reassure and help the Ministry of Health of Haiti and 
ministries of health of other countries to make the 
most eﬀ ective and eﬃ  cient use of OCV, with the aim of 
eliminating cholera.
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